Lisraya (brepocitinib) becomes the first FDA-approved oral treatment option for adults with dermatomyositis, introducing targeted TYK2/JAK1 inhibition into a disease long managed with steroids and broad immunomodulation.
Key Takeaways
- The FDA approved Lisraya (brepocitinib) on August 27, 2026, for adults with dermatomyositis.
- Lisraya is the first FDA-approved oral treatment option for dermatomyositis and inhibits the intracellular kinases TYK2 and JAK1.
- In the Phase 3 VALOR trial, the mean Total Improvement Score at Week 52 was 46.5 with brepocitinib 30 mg versus 31.2 with placebo.
Data Snapshot
| Item | Details |
|---|---|
| Drug | Lisraya (brepocitinib) |
| Company | Priovant Therapeutics / Roivant |
| Originator | Pfizer |
| Mechanism | TYK2/JAK1 inhibitor |
| Indication | Adults with dermatomyositis |
| Administration | Oral, once daily |
| Approved dose | 30 mg |
| Pivotal trial | Phase 3 VALOR |
| Trial size | 241 patients |
| TIS at Week 52 | 46.5 vs 31.2 |
| FDA approval | August 27, 2026 |
Lisraya (brepocitinib) is the first FDA-approved oral treatment for adults with dermatomyositis and inhibits the intracellular kinases TYK2 and JAK1. (FDA approval)
What Happened
The FDA approved Lisraya (brepocitinib) for adults with dermatomyositis on August 27, 2026. Lisraya is taken once daily as a 30-mg oral tablet and targets TYK2 and JAK1, two kinases involved in inflammatory cytokine signaling.
The approval was supported by the Phase 3 VALOR trial, which randomized 241 adults to brepocitinib 30 mg, brepocitinib 15 mg or placebo for 52 weeks. At Week 52, the mean Total Improvement Score was 46.5 with brepocitinib 30 mg versus 31.2 with placebo, demonstrating significantly greater overall disease improvement. (VALOR Phase 3)
Independent coverage highlighted the significance of adding a convenient oral targeted therapy to a disease historically treated with corticosteroids, immunoglobulin infusions and other immunosuppressive therapies. (BioPharma Dive)
Why It Matters
Dermatomyositis is a systemic autoimmune disease that affects both skin and skeletal muscle, causing characteristic rashes, muscle weakness and other systemic complications.
Before Lisraya, the main FDA-approved disease-specific treatment was Octagam 10%, an intravenous immunoglobulin therapy approved for adult dermatomyositis in 2021. Many patients have also relied on corticosteroids and other immunosuppressive therapies.
Lisraya changes this treatment landscape by combining oral administration with targeted intracellular signaling inhibition. Rather than broadly modulating immune activity, brepocitinib inhibits TYK2/JAK1-dependent cytokine signaling and reduces downstream inflammatory responses.
Want to know how TYK2/JAK1 inhibition can suppress multiple inflammatory signals in dermatomyositis?
Read the BP Science explainer:
How Lisraya Targets Dermatomyositis Through TYK2/JAK1 Inhibition
BP View
Lisraya’s approval is important because it shifts dermatomyositis treatment toward a more targeted and convenient therapeutic model. Octagam established a disease-specific treatment option, but intravenous administration and broad immunomodulation leave room for an effective oral targeted therapy.
The competitive advantage is not only convenience. Brepocitinib acts on a shared intracellular signaling network used by multiple inflammatory cytokines, which may provide broader pathway coverage than therapies aimed at a single upstream cytokine.
Brepocitinib was originally discovered by Pfizer and later licensed to Priovant, which focused the asset on rare autoimmune diseases with substantial unmet need. Lisraya’s FDA approval provides regulatory and commercial validation for Priovant’s strategy of developing brepocitinib in rare autoimmune indications. (Reuters)
In my view, the next question is whether Lisraya can establish itself as the preferred targeted therapy before more selective competitors arrive. Pfizer’s anti-IFN-β antibody dazukibart is advancing in Phase 3, setting up a future comparison between broader downstream JAK-pathway inhibition and more selective upstream cytokine blockade.
Related Post
For another recent first-in-class FDA approval that introduced a new biological treatment strategy, read my previous analysis of Takeda’s Mimrylo in polycythemia vera.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Have a different view on this analysis or something you’d like to discuss? Leave a comment — I’d be happy to hear your thoughts.
Leave a Reply